The FDA keeps shutting down the good compounders first. It is not sabotage.
Pro RX and BPI both stopped compounding tirzepatide within a week of each other in April 2026. Both were among the more reputable operators in the space. Neither got a slow warning-letter runway. The community read it fast: the FDA goes after the good vendors first, on purpose, to break the self-treatment infrastructure people actually trust.
The pattern is real. The motive is wrong. And if you use the wrong motive to pick a vendor, it will cost you.
The pattern people are seeing is real
From where a user stands, the observation holds up. Two named, reputable tirzepatide compounders went down inside a week. The causal chain was public: insurance excluded GLP-1s, that pushed patients to compounding pharmacies, then the FDA started shutting those pharmacies down, leaving a policy vacuum.
Meanwhile the anonymous "research use only" resellers kept shipping. The FDA did issue warning letters to gray-market vendors like Pink Pony Peptides and Gram Peptides on March 31, 2026, but a warning letter to an offshore-payment RUO shop is not the same event as a licensed pharmacy losing its ability to operate. So yes: the legitimate, US-facing operators took the hard hit while the gray shops stayed up. That is the real observation the "deliberate" theory is built on.
Why "deliberate destabilization" gets it wrong
Three boring reasons, none of which need any intent to break trusted infrastructure.
1. Legality, not quality
Compounding is a rules engine, not a judgment call. A 503A pharmacy can compound a drug when it uses an approved ingredient, sits on a qualifying bulks list, or is covered by an active drug shortage. Compounded tirzepatide was riding the shortage pathway. When the shortage resolved, compounding an FDA-approved drug lost its legal footing regardless of how clean the product was.
Pro RX and BPI were not shut down for being bad. They were shut down for compounding a now-off-shortage approved drug, which is exactly what a compliant, high-volume tirzepatide operator does. Quality had nothing to do with it.
2. Visibility
A licensed pharmacy has a name, an address, a prescriber network, and a website that markets. It is a fixed, traceable, high-value target. A research-use-only reseller behind an offshore processor and a "not for human consumption" label is built to be hard to serve. The reputable operator is easier to find and easier to close, not because anyone prefers to hurt patients, but because legitimacy and legal exposure sit on the same surface.
3. Marketing is the sharpest vector
The Novo v. Hims fight showed where real legal pressure lands: on what companies claim and how they market it. The operators making the boldest health claims draw the letter first. Building a reputation and making claims go together, so the vendor that looks most trustworthy is often the one that has said the most on the record.
What this means when you pick a vendor
Here is the counterintuitive part. Right now, "looks most legitimate" and "most enforcement-exposed" overlap. A named US operator compounding an approved GLP-1 that just came off shortage, marketing it with confident claims, is not the safe harbor it looks like. It is the next name on the list. Before you read a polished site as a safety signal, work the vendor the way we vet one.
That is not an argument to run to the gray market. The RUO shops survive because they are hard to catch, not because their product is safe, and the premium a clinic charges buys real things. The point is narrower: read enforcement risk as a function of legality, visibility, and claims, not vendor reputation. The reason US and EU rules diverge is the same rules-engine logic underneath.
The next test is days away
The FDA's Pharmacy Compounding Advisory Committee votes July 23-24, 2026 on 7 compounds: BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, and Epitalon. A yes vote moves them to Category 2 and ends compounding access.
If it lands, the same dynamic repeats one tier down. The visible, named, US-facing operators compounding those seven go first, and the anonymous resellers keep shipping. Watch the feed that week for which vendors go quiet.
The self-treatment infrastructure is not being targeted for being trusted. It is being caught for being visible. Those are not the same problem, and only one of them tells you what to do next.